Kannan Raman

Kannan Raman

*This is an algorithmically generated author record based on publicly available information.

Kannan Raman has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Retracted
    Open Access

    RETRACTED: Nano-Innovations for a Greener Future: Exploring the Intersection of Nanotechnology and Environmental Sustainability

    by P.K. Hemalatha, Kuppusamy Kanagaraj, Kannan Raman, Senthilkumar Nangan, Ramesh, Saurabh Aggarwal, Rohit Kumar

    We take a zero tolerance to any situation where fraudulent research is published in our journals. As a result, this article has been retracted by the Publisher because it is suspected to be a nonsensical computer-generated publication with a number of tortured phrases and irrelevant references. Additional measures have been implemented to prevent these issues from reoccurring. EDP Sciences is extremely grateful to anonymous whistleblowers and the Problematic Paper Screener for bringing this case to our attention for further investigations.


  • Biomarkers of Alzheimer’s Disease

    by Ashok Kumar Janakiraman, Hanish Singh Jayasingh Chellammal, Kannan Raman, Ramkanth Sundarapandian, Kushagra Khanna, Dhani Ramachandran, Mullaicharam Bhupathyraaj, Cheng Zenli

  • Biomarkers of Alzheimer’s Disease

    by Ashok Kumar Janakiraman, Hanish Singh Jayasingh Chellammal, Kannan Raman, Ramkanth Sundarapandian, Kushagra Khanna, Dhani Ramachandran, Mullaicharam Bhupathyraaj, Cheng Zenli

  • Retraction
    Open Access

    Retraction Notice: Nano-Innovations for a Greener Future: Exploring the Intersection of Nanotechnology and Environmental Sustainability

    by P.K. Hemalatha, Kuppusamy Kanagaraj, Kannan Raman, Senthilkumar Nangan, Ramesh, Saurabh Aggarwal, Rohit Kumar

    We take a zero tolerance to any situation where fraudulent research is published in our journals. As a result, this article has been retracted by the Publisher because it is suspected to be a nonsensical computer-generated publication with a number of tortured phrases and irrelevant references. Additional measures have been implemented to prevent these issues from reoccurring. EDP Sciences is extremely grateful to anonymous whistleblowers and the Problematic Paper Screener for bringing this case to our attention for further investigations.

  • Open Access

    Drug target of natural products and COVID-19: how far has science progressed?

    by Kannan Raman, Kalirajan Rajagopal, B. Ramesh, P. Kumar Nallasivan, M. K. Mohan Maruga Raja, Srikanth Jupudi, Gowramma Byran, Sharuk L. Khan, Talha Bin Emran

    The new coronavirus [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] that caused a viral disease with a high risk of mortality (coronavirus disease 2019) was found toward the end of 2019. This was a significant acute respiratory syndrome. In a brief period, this virus spread throughout the entire planet, causing tremendous loss of life and economic damage. The process of developing new treatments takes time, and there are presently no recognized specific treatments to treat this infection. The most promising participants, who subsequently developed into prospective leads, were dropped from the clinical research in their latter phases. Medication that has previously acquired permission may only be repurposed for use for various medical reasons following a thorough investigation for safety and effectiveness. Because there are now no effective treatments available, natural products are being used haphazardly as antiviral medications and immunity boosters. The fundamental statement that most natural compounds have powerful antiviral action does not apply to SARS-CoV-2. Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus infections are inhibited by natural treatments. According to an in silico study, the virus’ nonstructural proteins, including PLpro, Mpro, and RdRp, as well as structural proteins like the spike (S) protein, have been shown to have a strong affinity for several natural products and to be inhibited by them. The virus also suggests that it is a valid candidate for therapeutic research since it utilizes the intracellular angiotensin-converting enzyme 2 receptor of the host cell. In this study, interesting targets for SARS-CoV-2 medication development are explored, as well as the antiviral properties of some well-known natural compounds.


  • Open Access

    Acridine as an Anti-Tumour Agent: A Critical Review

    by Potlapati Varakumar, Kalirajan Rajagopal, Baliwada Aparna, Kannan Raman, Gowramma Byran, Clara Mariana Gonçalves Lima, Salma Rashid, Mohammed H. Nafady, Talha Bin Emran, Sławomir Wybraniec

    This review summarized the current breakthroughs in the chemistry of acridines as anti-cancer agents, including new structural and biologically active acridine attributes. Acridine derivatives are a class of compounds that are being extensively researched as potential anti-cancer drugs. Acridines are well-known for their high cytotoxic activity; however, their clinical application is restricted or even excluded as a result of side effects. The photocytotoxicity of propyl acridine acts against leukaemia cell lines, with C1748 being a promising anti-tumour drug against UDP-UGT’s. CK0403 is reported in breast cancer treatment and is more potent than CK0402 against estrogen receptor-negative HER2. Acridine platinum (Pt) complexes have shown specificity on the evaluated DNA sequences; 9-anilinoacridine core, which intercalates DNA, and a methyl triazene DNA-methylating moiety were also studied. Acridine thiourea gold and acridinone derivatives act against cell lines such as MDA-MB-231, SK-BR-3, and MCF-7. Benzimidazole acridine compounds demonstrated cytotoxic activity against Dual Topo and PARP-1. Quinacrine, thiazacridine, and azacridine are reported as anti-cancer agents, which have been reported in the previous decade and were addressed in this review article.


  • Open Access

    Role of natural products towards the SARS-CoV-2: A critical review

    by Kannan Raman, Kalirajan Rajagopal, Fahadul Islam, Manish Dhawan, Saikat Mitra, Baliwada Aparna, Potlapati Varakumar, Gowramma Byran, Om Prakash Choudhary, Talha Bin Emran

    Despite the fact that various therapeutic compounds are being investigated, there is still a scarcity of effective and reliable therapeutic regimens to treat COVID-19. Ever since the COVID-19 pandemic, a diversity of traditional herbal treatments has been investigated to cure infected people, either alone or in conjunction with mainstream pharmaceuticals, with encouraging outcomes. In this article, we look at the latest research on the usage of natural products to alleviate the severity of COVID-19. To determine the activity of the natural products, act against SARS-CoV-2 to various targets like Mpro, ACE-II, papain-like, chymotrypsin-like proteases, and some antiviral targets. The processes underlying this preventative or therapeutic action are also examined. We used PubMed, Scopus, Google Scholar, and the WHO site to perform our review. The anti-SARS-CoV-2 impacts of various herbal extracts and purified compounds may be mediated via direct prevention of viral replication or entrance. Interestingly, certain items might avert SARS-CoV-2 from infecting human cells by blocking the ACE-2 protein or the serine protease TMPRRS2. Natural products have also been stated to suppress proteins intricate in the virus life cycle, like papain-like and chymotrypsin-like proteases. To conclude, natural products can be used alone or in combination as remedies or treatments for COVID-19. In addition, their compositions may provide insight into the development of effective and reliable antiviral drugs.